Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last week:

‍Blogs :

Education Level, Social Media Awareness May Be Linked to Cancer Fatalism

The SEQUOIA Trial: Zanubrutinib vs. BR in Previously Untreated CLL/SLL

Emerging Data on BTKi Resistance: Expert Insights and Treatment Implications

Real-World Safety Data for BTK Inhibitors in CLL from EHA 2024

Applying BTK Inhibitor Data to Clinical Decision-Making

Reducing Infections in Patients With CLL, NHL

Ponatinib and Blinatumomab in Newly Diagnosed Ph-Positive ALL

Future Treatment Directions and Ongoing Trials in Chronic Lymphocytic Leukemia

Navigating Second-Line Treatment Options in Chronic Lymphocytic Leukemia

Matching-Adjusted Indirect Comparisons of BTK Inhibitors for CLL

"Once you choose hope, anything’s possible"

Choosing BTK Inhibitors vs. Other Regimens for Chronic Lymphocytic Leukemia

MRD-Negative ALL: Addition of Blinatumomab
‍
‍Also at MCH the News and Tweets never stop flowing!

Join Us at www.mycancerhaven.org

‍The Team @ MCH

Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.